News Headline: Lilly Lung Cancer Drug Performs in Tests
Outlet Full Name: Indianapolis Star
Author: Jeff Swiatek
A lung cancer drug in testing by Eli Lilly and Co. performed well in a late-phase patient trial.
The Indianapolis drug maker said today that its experimental drug ramucirumab plus standard chemotherapy helped patients with non-small cell lung cancer live longer than patients who received just the standard chemotherapy.
Lilly said its scientists are pleased with the study results, which won’t be released in detail until later this year. The trial, called REVEL, enrolled more than 1,200 cancer patients whose disease had progressed even after getting platinum-based chemotherapy.
“These data reinforce our confidence in the overall ramucirumab development program,” said Dr. Richard Gaynor, senior vice president for product development and medical affairs for Lilly Oncology.
Lilly aims to bring ramucirumab to market as a second-line treatment for patients with lung cancer.
The need for a better lung cancer treatment is great. Lung cancer is responsible for nearly 30 percent of all U.S. cancer deaths, more than from breast, colon and prostate cancers combined, according to the American Cancer Society.
At 11:15 a.m., Lilly stock was trading up 2.8 percent or $1.54 on the day, to $56.80.